National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 508908

Case Details

VAERS ID: 508908 (history)  
Form: Version 1.0  
Age: 14.0  
Sex: Female  
Location: Foreign  
   Days after vaccination:0
Submitted: 2013-10-22
   Days after onset:594
Entered: 2013-10-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route

Administered by: Other       Purchased by: Other
Symptoms: Disturbance in attention, Dizziness, Injection site pain, Malaise, Mental impairment, Nasopharyngitis, Nausea, Urticaria
SMQs:, Anaphylactic reaction (broad), Acute pancreatitis (broad), Angioedema (narrow), Anticholinergic syndrome (broad), Dementia (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Extravasation events (injections, infusions and implants) (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Depression (excl suicide and self injury) (broad), Vestibular disorders (broad), Hypersensitivity (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Hypoglycaemia (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Diagnostic Lab Data: UNK
CDC Split Type: B0931152A

Write-up: This case was reported by a physician and described the occurrence of thinking reduced in a 16-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Historic vaccination included 1st and 2nd dose of CERVARIX (.5 ml, intramuscular; unknown site of injection and batch number) given in 2011. On 6 March 2012, the subject received 3rd dose of CERVARIX (.5 ml, intramuscular, unknown site of injection at the left side and batch number). On 6 March 2012, during vaccination with CERVARIX, the subject experienced injection site pain. One year after the vaccination with the third dose of CERVARIX, the subject presented with common cold and visited the hospital. On 3 October 2013, the subject presented with urticaria and visited the hospital. On 10 October 2013, the subject visited the hospital and presented with giddiness and malaise. On 11 October 2013, the subject presented with the giddiness and queasy. Furthermore, the subject recently complaint that she was not able to concentrate on her study and her academic performance had declined (reduced thinking). The physician considered the events were clinically significant (or requiring intervention). At the time of reporting the outcome of the events was unspecified. The physician considered that urticaria was unrelated to vaccination with CERVARIX.

New Search

Link To This Search Result:

Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166